DE3238554C2 - - Google Patents
Info
- Publication number
- DE3238554C2 DE3238554C2 DE3238554A DE3238554A DE3238554C2 DE 3238554 C2 DE3238554 C2 DE 3238554C2 DE 3238554 A DE3238554 A DE 3238554A DE 3238554 A DE3238554 A DE 3238554A DE 3238554 C2 DE3238554 C2 DE 3238554C2
- Authority
- DE
- Germany
- Prior art keywords
- ifn
- dna
- gene
- polypeptide
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/30—Signal or leader sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
- 1. Menschliches Gewebe, beispielsweise Milzgewebe oder periphere Blutlymphozyten werden mit Mitogenen gezüchtet, um die Bildung von Immuninterferon zu stimu lieren.
- 2. Zellpellets aus diesen Zellkulturen wurden in Gegenwart von Ribonuclease-Inhibitor extrahiert, um sämtliche zytoplasmatische RNA zu isolieren.
- 3. Eine Oligo-dT-Säule isolierte die gesamte meßenger-RNA (mRNA) in polyadenylierter Form. Diese mRNA wurde unter Verwendung eines Saccharose-Dichtegradienten und der Säure-Harnstoff-Gelelektrophorese einer Größenfraktionierung unterworfen.
- 4. Die entsprechende mRNA (12 bis 18 S) wurde in die entsprechende einzelsträngige komplementäre DNA (cDNA) umgewandelt, aus der doppelsträngige cDNA gebildet wurde. Nach poly-dC-tailing wurde sie in einen Vektor, z. B. ein Plasmid mit einem oder mehreren phänotypischen Markern, eingesetzt.
- 5. Die auf diese Weise hergestellten Vektoren wurden zur Transformation von Bakterienzellen unter Bildung einer Koloniebibliothek verwendet. Sowohl aus induzierter als auch aus nicht-induzierter mRNA (auf die vorstehende Weise erhalten) hergestellte radioaktiv markierte cDNA wurde zur getrennten Ermittlung von doppelten Koloniebibliotheken verwendet. Der Überschuß an cDNA wurde sodann entfernt. Die Kolonien wurden auf Röntgenfilme aufgebracht, um die induzierten cDNA-Klone zu identifizieren.
- 6. Von den induzierten cDNA-Klonen wurde die entsprechende Plasmid-DNA isoliert und sequenziert.
- 7. In einer ersten Ausführungsform wurde die sequenzierte DNA sodann in vitro zur Einfügung in einen entsprechenden Expressionsträger zugeschnitten, der zur Transformierung einer E. coli-Wirtszelle verwendet wurde, die wiederum in einem Medium gezüchtet wurde und die Expression des gewünschten Human-Immuninterferonprodukts durchführte.
- 8. Das auf diese Weise experimierte Human-Immuninterferon weist in seiner reifen Form zweifelsfrei 146 Aminosäuren auf, wobei am Beginn Cystein steht, und besitzt einen sehr stark basischen Charakter. Sein monomeres Molekulargewicht wurde mit 17 140 berechnet. Das Molekül kann sich zu oligomeren Formen, z. B. zur dimeren, trimeren oder tetrameren Form, assoziieren, was möglicherweise auf die Anwesenheit von zahlreichen basischen Resten, hydrophobe Eigenschaften, Salzbrückenbildung und dergleichen zurückzuführen ist. Die hohen Molekulargewichte, die früher bei natürlichem Material festgestellt wurden (6), die auf der Basis der Aminosäuresequenz allein nicht erklärbar sind, mögen auf derartige oligomeren Formen sowie auf den Kohlenhydratbeitrag aufgrund von Glycoxylierung nach der Translation zurückzuführen sein.
- 9. In bestimmten Wirtszellsystemen, insbesondere bei Ligatur in einem Expressionsträger, so daß eine Expression zusammen mit dem Signalpeptid stattfindet, wird die reife Form von Human-Immuninterferon in das Zellkulturmedium ausgebracht, was eine unermeßliche Hilfe bei Gewinnungs- und Reinigungsverfahren bedeutet.
JA300 (thr leuB6 thi thyA trpC1117 hsdm- hsdR- strR (20)
wurde zur Selektierung von Plasmiden mit einem Gehalt an funktionellem TRPI-Gen verwendet. Der Hefestamm RH2 18 mit dem Genotyp (trp1 ga12 SUC2 mal CUPI) (18) wurde als Hefetransformationswirt verwendet. RH2 18 ist ohne Einschränkungen bei der American Type Culture Collection unter der Nr. ATCC 44076 hinterlegt. M9 (Minimalmedium) mit 0,25 Prozent Casaminsäuren (CAA) und LB (rich medium) entsprechen den Angaben von Miller (58), wobei die Medien nach Autoklavisierung und Kühlung mit 20 µg/ml Ampicillin versetzt wurden. Hefe wurde auf folgenden Medien gezüchtet: YEPD mit einem Gehalt an 1 Prozent Hefeextrakt, 2 Prozent Pepton und 2 Prozent Glucose± 3 Prozent Difco-Agar. YNB+CAA enthielt 6,7 g Hefe-Stickstoffbase (ohne Aminosäuren (YNB), 10 mg Adenin, 10 mg Uracil, 5 g CAA, 20 g Glucose und±30 g Agar pro Liter.
- 1. Extraktion der Zellen in einem Lysepuffer (etwa pH 8) von hoher Leitfähigkeit mittels Passage durch einen Homogenisator bei hohem Druck, Abkühlen des Abstroms in einem Eisbad.
- 2. Ausfällung der DNA durch Zugabe von Polyethylenimin unter Rühren z. B. bei 4°C.
- 3. pH-Ausfällung der bakteriellen Proteine, wobei wiederum IFN-γ in Lösung bleibt.
- 4. Abzentrifugieren der Feststoffe bei 4°C.
- 5. Konzentrieren des Überstands (nach erneuter Einstellung des pH) z. B. durch Ultrafiltration.
- 6. Dialyse des Konzentrats gegen einen Puffer von niedriger Leitfähigkeit.
- 7. Abzentrifugieren der Feststoffe, wobei IFN-γ in Lösung bleibt.
- 8. Ionenaustauschchromatographie an Carboxymethylcellulose, Elution mit einem Gradienten an zunehmender Ionenstärke.
- 9. Chromatographie an Calciumphosphat-Gel und Elution mit einem Gradienten an zunehmender Ionenstärke.
- 10. Ionenaustauschchromatographie an Carboxymethylcellulose unter schwach denaturierenden Bedingungen und Elution mit einem Gradienten an zunehmender Ionenstärke.
- 11. Abtrennung durch Gelfiltrationschromatographie.
2. Goeddel et al., Nature 290, 20 (1981).
3. Yelverton et al., Nucleic Acids Research 9, 731 (1981).
4. Gutterman et al., Annals of Int. Med. 93, 399 (1980).
5. Goeddel et al., Nucleic Acids Reseach 8, 4057 (1980).
6. Yip et al., Proc. Natl. Acad. Sci. (USA) 78, 1601 (1981).
7. Taniguchi et al., Proc. Natl. Acad. Sci. (USA) 78, 3469 (1981).
8. Bloom, Nature 289, 593 (1980).
9. Sonnenfeld et al., Cellular Immunol. 40, 285 (1978).
10. Fleishmann et al., Infection and Immunity 26, 248 (1979).
11. Blalock et al., Cellular Immunology 49, 390 (1980).
12. Rudin et al., Proc. Natl. Acad. Sci. (USA) 77, 5928 (1980).
13. Crane et al., J. Natl. Caner Inst. 61, 871 (1978).
14. Stinchcomb et al., Nature 282, 39 (1979).
15. Kingsman et al., Gene 7, 141 (1979).
16. Tschumper et al., Gene 10, 157 (1980).
17. Mortimer et al., Microbiological Reviews 44, 519 (1980).
18. Miozzari et al., Journal of Bacteriology 134, 48 (1978).
19. Jones, Genetics 85, 23 (1977).
20. Hitzeman, et al., J. Biol. Chem. 255, 12073 (1980).
21. Hess et al., J. Adv. Enzyme Regul. 7, 149 (1968).
22. Holland et al., Biochemistry 17, 4900 (1978).
23. Bostian et al., Proc. Natl. Acad. Sci. (USA) 77, 4504 (1980).
24. The Molecular Biology of Yeast (Aug 11-18, 1981), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
25. Chambon, Ann. Rev. Biochemistry, 44, 613 (1975).
25a. Gluzman, Cell 23, 175 (1981).
26. Goeddel et al., Nature 281, 544 (1979).
27. Itakura et al., Science 198, 1056 (1977).
28. Lusky et al., Nature 293, 79 (1981).
29. Gluzman et al., Cold Spring Harbor Symp. Quant. Biol. 44, 293 (1980).
30. Fiers et al., Nature 273, 113 (1978).
31. Reddy et al., Science 200, 494 (1978).
32. Boedtker et al., Prog. in Nucleic Acids Res. Mol. Biol. 19, 253 (1976).
33. Berger et al., Biochemistry 18, 5143 (1979).
34. Aviv et al., Proc. Natl. Acad. Sci. USA 69, 1408 (1972).
35. Gurdon et al., J. Molec. Biol. 80, 539 (1975).
36. Stewart, The Interferon System. Springer, New York, p. 13-26 (1979).
37. Lehrach et al., Biochemistry 16, 4743 (1977).
38. Lynch et al., Virology 98, 251 (1979).
39. Wickens et al., J. Biol. Chem. 253, 2483 (1978).
40. Chang et al., Nature 275, 617 (1978).
41. Bolivar et al., Gene 2, 95 (1977).
42. Grunstein et al., Proc. Natl. Acad. Sci. U.S.A. 72, 3961 (1975).
43. Fritsch et al., Cell 19, 959 (1980).
44. Birnboim et al., Nucleic Acids Res. 7, 1513 (1979).
45. Kafatos et al., Nucleic Acids Res. 7, 1541 (1979).
46. Clewell et al., Biochemistry 9, 4428 (1970).
47. Taylor et al., Biochim. Biophys. Acta 442, 324 (1976).
48. Smith, Methods Enzymol. 65, 560 (1980).
49. Messing et al., Nucleic Acids Res. 9, 309 (1981).
50. Winzler, Hormonal Proteins and Peptides (ed. Li) Academic Press, New York, p. 1 (1973).
51. Nathan et al., Nature 292, 842 (1981).
52. Maxam et al., Methods in Enzymol. 65, 490 (1980).
53. Crea et al., Proc. Natl. Acad. Sci. (USA) 75, 5765 (1978).
54. Southern, J. Molec. Biol. 98, 503 (1975).
55. Blin et al., Nucleic Acids Res. 3, 2303 (1976).
56. Lawn et al., Science 212, 1159 (1981).
57. Lawn et al., Nucleic Acids Res. 9, 1045 (1981).
58. Miller, Experiments in Molecular Genetics, p. 431-3, Cold Spring Harbor Lab., Cold Spring Harbor, New York (1972).
59. Beggs, Nature 275, 104 (1978).
60. Valenzuela et al., Animal Virus Genetics (ed. Fields, Jaenisch and Fox) p. 57, Academic Press, New York (1980).
61. McCuthan et al., J. Natl. Cancer Inst. 41, 351 (1968).
Claims (16)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31248981A | 1981-10-19 | 1981-10-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3238554A1 DE3238554A1 (de) | 1983-05-05 |
DE3238554C2 true DE3238554C2 (de) | 1989-11-23 |
Family
ID=23211703
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198282305521T Pending DE77670T1 (de) | 1981-10-19 | 1982-10-18 | Humanes immuninterferon. |
DE8282305521T Expired DE3279788D1 (en) | 1981-10-19 | 1982-10-18 | Human immune interferon |
DE19823238554 Granted DE3238554A1 (de) | 1981-10-19 | 1982-10-18 | Human-immuninterferon |
DE1993175065 Active DE19375065I2 (de) | 1981-10-19 | 1982-10-18 | Humanes Immuninterferon. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198282305521T Pending DE77670T1 (de) | 1981-10-19 | 1982-10-18 | Humanes immuninterferon. |
DE8282305521T Expired DE3279788D1 (en) | 1981-10-19 | 1982-10-18 | Human immune interferon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1993175065 Active DE19375065I2 (de) | 1981-10-19 | 1982-10-18 | Humanes Immuninterferon. |
Country Status (43)
Country | Link |
---|---|
US (4) | US4762791A (de) |
EP (1) | EP0077670B1 (de) |
JP (3) | JPS5890514A (de) |
KR (1) | KR840001837A (de) |
AT (1) | ATE44289T1 (de) |
AU (1) | AU561343B2 (de) |
BG (2) | BG44877A3 (de) |
BR (1) | BR8206068A (de) |
CA (1) | CA1341590C (de) |
CH (1) | CH663619A5 (de) |
CZ (1) | CZ282154B6 (de) |
DD (1) | DD208822A5 (de) |
DE (4) | DE77670T1 (de) |
DK (1) | DK163187C (de) |
DZ (1) | DZ467A1 (de) |
ES (1) | ES516620A0 (de) |
FI (1) | FI86559C (de) |
FR (1) | FR2514783B1 (de) |
GB (1) | GB2107718B (de) |
GR (1) | GR78391B (de) |
GT (1) | GT198277746A (de) |
HK (1) | HK66289A (de) |
HU (1) | HU202287B (de) |
IE (1) | IE54371B1 (de) |
IL (1) | IL66992A (de) |
IT (1) | IT1153265B (de) |
LU (1) | LU88327I2 (de) |
MX (2) | MX166499B (de) |
MY (1) | MY102546A (de) |
NL (1) | NL930040I2 (de) |
NO (2) | NO164177C (de) |
NZ (1) | NZ202190A (de) |
OA (1) | OA07233A (de) |
PH (1) | PH26963A (de) |
PL (1) | PL153202B1 (de) |
PT (1) | PT75696B (de) |
RO (1) | RO89534A (de) |
RU (3) | RU2056460C1 (de) |
SG (1) | SG76988G (de) |
SK (1) | SK279535B6 (de) |
YU (1) | YU45871B (de) |
ZA (1) | ZA827569B (de) |
ZW (1) | ZW22282A1 (de) |
Families Citing this family (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
ZW18282A1 (en) * | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
JPS58146281A (ja) * | 1981-10-19 | 1983-08-31 | Suntory Ltd | 酵母細胞の形質転換法 |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
JPS62223191A (ja) * | 1981-12-24 | 1987-10-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチドの製法 |
JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
US5004689A (en) * | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
ZA831094B (en) * | 1982-02-22 | 1983-11-30 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides |
GB8406910D0 (en) * | 1984-03-16 | 1984-04-18 | Biogen Nv | Gamma interferon |
IE54592B1 (en) * | 1982-03-08 | 1989-12-06 | Genentech Inc | Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby |
US6432677B1 (en) | 1982-03-08 | 2002-08-13 | Genentech, Inc. | Non-human animal interferons |
US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
IL68100A0 (en) * | 1982-03-24 | 1983-06-15 | Takeda Chemical Industries Ltd | Novel dna and use thereof |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
JPH0787797B2 (ja) * | 1982-05-20 | 1995-09-27 | サントリー株式会社 | ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法 |
AU577259B2 (en) * | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
AU571460B2 (en) * | 1982-09-27 | 1988-04-21 | Cancer Institute Of Japanese Foundation For Cancer Research | Alpha interferon dna, recombinant plasmid, engineered organism and alpha interferon polypeptide |
AU575301B2 (en) * | 1982-10-08 | 1988-07-28 | Juridical Foundation, Japanese Foundation For Cancer Research | Novel vector |
US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
WO1984002129A1 (en) * | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
GR79124B (de) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4518526A (en) * | 1982-12-22 | 1985-05-21 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
JPH0740925B2 (ja) * | 1983-03-14 | 1995-05-10 | 協和醗酵工業株式会社 | 新規ヒトインタ−フエロン−γポリペプチド |
US7198919B1 (en) * | 1983-04-25 | 2007-04-03 | Genentech, Inc. | Use of alpha factor sequences in yeast expression systems |
ZA843275B (en) * | 1983-05-05 | 1984-12-24 | Hoffmann La Roche | Novel vectors for interferon expression |
ZA844082B (en) * | 1983-06-01 | 1985-09-25 | Hoffmann La Roche | Polypeptides having interferon activity |
JP2551746B2 (ja) * | 1983-07-19 | 1996-11-06 | サントリー株式会社 | 改良プラスミドベクタ−およびその利用 |
JPS6034919A (ja) * | 1983-08-04 | 1985-02-22 | Green Cross Corp:The | ガンマ・インタ−フェロン組成物 |
EP0133767B1 (de) * | 1983-08-04 | 1991-04-03 | The Green Cross Corporation | Gamma-Interferonzusammensetzung |
IL72773A0 (en) * | 1983-08-29 | 1984-11-30 | Meloy Lab | Production of immune interferon and its mrna |
ZA846554B (en) * | 1983-09-20 | 1985-04-24 | Hoffmann La Roche | Immune interferon and method for its purification |
US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
US4604284A (en) * | 1983-09-20 | 1986-08-05 | Hoffmann-La Roche Inc. | Homogeneous immune interferon fragment |
US4476049A (en) * | 1983-09-20 | 1984-10-09 | Hoffmann-La Roche Inc. | Method for the extraction of immune interferon |
JPS6079000A (ja) * | 1983-10-04 | 1985-05-04 | Takeda Chem Ind Ltd | ヒトγ型インタ−フエロン単量体の製造法 |
JPH0788398B2 (ja) * | 1983-10-17 | 1995-09-27 | サントリー株式会社 | 新規生理活性ポリペプチドおよびその製造法 |
GB8328820D0 (en) * | 1983-10-28 | 1983-11-30 | Searle & Co | Synthetic human gamma interferon gene |
FR2556365B1 (fr) * | 1983-12-09 | 1987-07-31 | Transgene Sa | Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
JPS60145098A (ja) * | 1984-01-09 | 1985-07-31 | Suntory Ltd | 糖付加ポリペプチドの製造法 |
WO1985004420A1 (en) * | 1984-03-29 | 1985-10-10 | Takeda Chemical Industries, Ltd. | Novel dna and its use |
DE3414831A1 (de) * | 1984-04-19 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Herstellung von polypeptiden mit human-gammainterferon-aktivitaet |
GB8414354D0 (en) * | 1984-06-05 | 1984-07-11 | Biogen Nv | Purifying protein |
IL75302A0 (en) * | 1984-06-06 | 1985-09-29 | Takeda Chemical Industries Ltd | Novel polypeptide and production thereof |
WO1985005618A1 (en) * | 1984-06-06 | 1985-12-19 | Takeda Chemical Industries, Ltd. | Process for preparing interferon derivative |
CA1302320C (en) * | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
JPS60262594A (ja) * | 1984-06-11 | 1985-12-25 | Kanegafuchi Chem Ind Co Ltd | ヒトインタ−フエロン−γ |
GB8414911D0 (en) * | 1984-06-12 | 1984-07-18 | Searle & Co | Producing human gamma interferon |
JPS6124599A (ja) * | 1984-07-11 | 1986-02-03 | Kyowa Hakko Kogyo Co Ltd | 新規ヒトインタ−フエロン−rポリペプチド誘導体 |
GB2164650A (en) * | 1984-09-25 | 1986-03-26 | Fujisawa Pharmaceutical Co | Process for production of y-interferon |
ATE66375T1 (de) * | 1984-10-05 | 1991-09-15 | Bioferon Biochem Substanz | Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung. |
JPS6188875A (ja) * | 1984-10-05 | 1986-05-07 | Kanegafuchi Chem Ind Co Ltd | ヒトインタ−フエロン−γ |
US4946674A (en) * | 1984-10-05 | 1990-08-07 | Bioferon Biochemische Substanzen Gmbh & Co. | Process for treatment of rheumatic diseases |
DE3436638C2 (de) * | 1984-10-05 | 1992-10-08 | Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen |
IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
JPS61108397A (ja) * | 1984-10-31 | 1986-05-27 | Green Cross Corp:The | インタ−フエロン−γ蛋白質の製造法 |
AU598455B2 (en) * | 1984-12-27 | 1990-06-28 | Suntory Limited | Method for purifying an interferon |
JPS6156195A (ja) * | 1985-03-01 | 1986-03-20 | Asahi Chem Ind Co Ltd | 新規生理活性ペプチド |
GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
WO1986006077A1 (en) * | 1985-04-08 | 1986-10-23 | Amgen | A method and a hybrid promoter for controlling exogenous gene transcription |
US4873312A (en) * | 1985-04-25 | 1989-10-10 | Amgen | Method for purifying interferon and composition of matter produced thereby |
FR2583429B1 (fr) * | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
US4845196A (en) * | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
AU621277B2 (en) * | 1985-11-13 | 1992-03-12 | Xoma Corporation | Shortened phosphoglycerate kinase promoter |
US5104795A (en) * | 1985-11-13 | 1992-04-14 | Zoma Corporation | Shortened phosphoglycerate kinase promoter |
EP0237019A3 (de) * | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens |
US5198343A (en) * | 1986-08-05 | 1993-03-30 | Transgene, S.A. | Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained |
US6238889B1 (en) * | 1986-12-16 | 2001-05-29 | Dsm N.V. | Molecular cloning and expression of the Pro8 isoform of human IL-3 |
US4939088A (en) * | 1987-02-18 | 1990-07-03 | Meloy Laboratories Inc. | Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon |
US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
US6384194B1 (en) * | 1987-12-16 | 2002-05-07 | Dsm N.V. | Expression and purification of human interleukin-3 and muteins thereof |
US5258287A (en) * | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
IL90021A0 (en) * | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Process for the production of interferon |
US5198212A (en) * | 1988-10-31 | 1993-03-30 | University Of Lousville Research Foundation Incorporated | Method and compositions for treatment of trauma-associated sepsis with gamma interferon |
US20020168750A1 (en) * | 1988-12-23 | 2002-11-14 | James Rasmussen | Enzymatically active recombinant glucocerebrosidase |
US5236838A (en) * | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US6451600B1 (en) * | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5196191A (en) * | 1989-03-17 | 1993-03-23 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
US5112605A (en) * | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
AU5355790A (en) * | 1989-04-19 | 1990-11-16 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
DE4009268A1 (de) * | 1990-03-22 | 1991-09-26 | Consortium Elektrochem Ind | Sekretion von hirudinderivaten |
US5281520A (en) * | 1990-09-12 | 1994-01-25 | Zymogenetics, Inc. | Method for producing acyloxyacyl hydrolase |
ZA917669B (en) * | 1990-09-27 | 1992-08-26 | Schering Corp | Antagonists of human gamma interferon |
EP0487298A3 (en) * | 1990-11-21 | 1992-12-16 | Schering Corporation | Human gamma interferon antagonist/agonist screen |
AU1268192A (en) * | 1991-01-04 | 1992-08-17 | Board Of Regents, The University Of Texas System | Cloning and expression of tissue transglutaminases |
US5272078A (en) * | 1991-01-29 | 1993-12-21 | Brigham And Women's Hospital | CDNA encoding the type I iodothyronine 5'deiodinase |
AU1337092A (en) * | 1991-01-29 | 1992-08-27 | Brigham And Women's Hospital | A cdna encoding the type i iodothyronine 5' deiodinase |
WO1994003599A1 (en) * | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
AU5590394A (en) * | 1992-11-03 | 1994-05-24 | Oklahoma Medical Research Foundation | Transglutaminase gene |
ES2126094T3 (es) * | 1992-12-29 | 1999-03-16 | Genentech Inc | Tratamiento de la enfermedad inflamatoria de los intestinos con inhibidores del interferon-gamma. |
EP0982405B1 (de) | 1993-09-15 | 2009-08-26 | Novartis Vaccines and Diagnostics, Inc. | Rekombinante Alphavirus Vektoren |
DE69738521T2 (de) | 1996-04-05 | 2009-05-07 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen |
CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
US20020168634A1 (en) * | 1999-05-05 | 2002-11-14 | Christine Marie Debouck | Methods for identifiying genes essential to the growth of an organism |
BR9812267B1 (pt) * | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
ES2314786T3 (es) | 1998-04-02 | 2009-03-16 | Genentech, Inc. | Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca. |
JP2002533124A (ja) | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Hivポリペプチドの改善された発現およびウイルス様粒子の生成 |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7230081B1 (en) | 1999-11-12 | 2007-06-12 | Maxygen Holdings, Ltd. | Interferon gamma conjugates |
SK8292002A3 (en) | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
EP1276756A4 (de) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusionsproteine |
JP4873818B2 (ja) * | 2000-05-16 | 2012-02-08 | ボルダー バイオテクノロジー, インコーポレイテッド | 遊離システイン残基を含有するタンパク質をリフォールディングする方法 |
AU2587002A (en) * | 2000-11-03 | 2002-05-15 | Biomedicines Inc | Method for short-term and long-term drug dosimetry |
DE60239522D1 (de) * | 2001-01-09 | 2011-05-05 | Baylor Res Inst Dallas | Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays |
US7038015B2 (en) | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
US6958388B2 (en) | 2001-04-06 | 2005-10-25 | Maxygen, Aps | Interferon gamma polypeptide variants |
EP1411770A4 (de) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung |
CA2452119C (en) | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
EP1446162B1 (de) * | 2001-08-17 | 2008-10-15 | Coley Pharmaceutical GmbH | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
JP2005509647A (ja) * | 2001-11-06 | 2005-04-14 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | エストロゲン応答性乳癌の治療方法 |
EP1450849A4 (de) * | 2001-11-06 | 2005-06-29 | Applied Research Systems | Verfahren zur behandlung von endometreose |
EP1536839B1 (de) * | 2001-11-09 | 2010-09-15 | Intarcia Therapeutics, Inc | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen |
WO2003049760A1 (en) * | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
AU2003228751A1 (en) | 2002-05-01 | 2003-11-17 | Cell Genesys, Inc. | Lentiviral vector particles resistant to complement inactivation |
AU2003239774A1 (en) | 2002-07-03 | 2004-01-23 | Maxygen Holdings Ltd. | Full-length interferon gamma polypeptide variants |
AU2003251763A1 (en) * | 2002-07-03 | 2004-01-23 | The Brighamn And Women's Hospital, Inc. | Interferon gamma in the detection and treatment of angiomyolipomas |
AU2003285874A1 (en) | 2002-10-16 | 2004-05-04 | Amgen Inc. | HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP1697415A1 (de) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | Polypeptidvarianten, die an den neonatal-fc-receptor (fcrn) binden, dimere fc-bindende proteine und damit in zusammenhang stehende verfahren |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
WO2006050394A2 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
EP2364995A1 (de) | 2004-12-23 | 2011-09-14 | Molmed SpA | Konjugatprodukt |
SG173313A1 (en) | 2005-01-05 | 2011-08-29 | Biogen Idec Inc | Cripto binding molecules |
ES2381203T3 (es) * | 2005-01-27 | 2012-05-24 | Novimmune Sa | Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
EP2102355B1 (de) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung |
PT2157967E (pt) | 2007-04-23 | 2013-04-03 | Intarcia Therapeutics Inc | Formulações de suspensões de péptidos insulinotrópicos e suas utilizações |
NZ580686A (en) * | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
US20090155838A1 (en) * | 2007-11-28 | 2009-06-18 | Smart Tube, Inc. | Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample |
CN103694337B (zh) | 2008-02-08 | 2016-03-02 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
EP2248903A1 (de) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen |
KR102148624B1 (ko) | 2009-09-28 | 2020-08-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
KR20140002601A (ko) | 2010-07-09 | 2014-01-08 | 바이오겐 이데크 헤모필리아 인코포레이티드 | 키메라 응고 인자 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
RU2446172C1 (ru) * | 2011-03-24 | 2012-03-27 | Общество С Ограниченной Ответственностью "Фармапарк" | Способ получения зрелого интерферона альфа-2 человека с использованием дрожжей saccharomyces cerevisiae и штамм-продуцент интерферона альфа-2 человека (варианты) |
EA023379B1 (ru) * | 2011-06-21 | 2016-05-31 | Общество С Ограниченной Ответственностью "Фарма Ген" | ШТАММ ESCHERICHIA COLI BL21(DE3)-pIE-GAMMA И СПОСОБ ПОЛУЧЕНИЯ ПРЕПАРАТА НАТИВНОГО РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА ГАММА ЧЕЛОВЕКА |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
WO2013024158A1 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
WO2013024156A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
AU2013207927B2 (en) | 2012-01-10 | 2017-11-02 | Biogen Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
US20140350087A9 (en) | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
EP2870238A4 (de) | 2012-07-05 | 2016-03-09 | Ohio State Innovation Foundation | Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen |
WO2014033266A1 (en) | 2012-08-31 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection |
UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
EP2940128A1 (de) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus mit einem albuminbindenden Teil |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3253875B1 (de) | 2015-02-04 | 2020-01-08 | H. Hoffnabb-La Roche Ag | Tau-antisense-oligomere und verwendungen davon |
CN107636159B (zh) | 2015-02-04 | 2022-06-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
SG10202108996PA (en) | 2015-05-07 | 2021-09-29 | Swedish Orphan Biovitrum Ag | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
KR20240042548A (ko) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
CN108348593B (zh) | 2015-08-31 | 2022-08-16 | 泰克诺瓦克斯股份有限公司 | 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗 |
WO2017180770A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
CN110073002B (zh) | 2016-10-17 | 2024-06-11 | 杨森制药公司 | 重组病毒复制子体系及其用途 |
KR102655641B1 (ko) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
WO2019040740A1 (en) | 2017-08-23 | 2019-02-28 | Wayne State University | IMMUNO IMAGING IN VIVO OF INTERFERON GAMMA |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
EP3740245A4 (de) | 2018-01-19 | 2022-01-05 | Janssen Pharmaceuticals, Inc. | Auslösung und verstärkung von immunreaktionen unter verwendung rekombinanter replikonsysteme |
AU2021237818A1 (en) | 2020-03-19 | 2022-09-29 | Trizell Ltd. | Temperature-responsive virus storage system |
US20230226154A1 (en) | 2020-03-30 | 2023-07-20 | Trizell Ltd. | Compositions and methods for treating cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4332892A (en) * | 1979-01-15 | 1982-06-01 | President And Fellows Of Harvard College | Protein synthesis |
JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
AU538665B2 (en) * | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
GB2068970B (en) * | 1980-02-06 | 1983-06-22 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4460685A (en) * | 1980-05-29 | 1984-07-17 | New York University | Method of enhancing the production of human γ Interferon |
FI64813C (fi) * | 1980-12-31 | 1984-01-10 | Ilkka Antero Palva | Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer |
US4376821A (en) * | 1981-04-17 | 1983-03-15 | Meloy Laboratories, Inc. | Production of human IFN-gamma (immune) interferon |
IL65475A0 (en) * | 1981-04-17 | 1982-07-30 | Meloy Lab | Production of immune interferon and its mrna |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
-
1982
- 1982-10-14 AU AU89352/82A patent/AU561343B2/en not_active Expired
- 1982-10-15 ZA ZA827569A patent/ZA827569B/xx unknown
- 1982-10-15 IL IL66992A patent/IL66992A/xx not_active IP Right Cessation
- 1982-10-15 NZ NZ202190A patent/NZ202190A/en unknown
- 1982-10-15 FI FI823528A patent/FI86559C/fi not_active IP Right Cessation
- 1982-10-15 PH PH27993A patent/PH26963A/en unknown
- 1982-10-15 ZW ZW222/82A patent/ZW22282A1/xx unknown
- 1982-10-16 KR KR1019820004666A patent/KR840001837A/ko unknown
- 1982-10-17 DZ DZ826687A patent/DZ467A1/fr active
- 1982-10-18 BR BR8206068A patent/BR8206068A/pt unknown
- 1982-10-18 DE DE198282305521T patent/DE77670T1/de active Pending
- 1982-10-18 AT AT82305521T patent/ATE44289T1/de active
- 1982-10-18 IT IT23795/82A patent/IT1153265B/it active
- 1982-10-18 BG BG8676612A patent/BG44877A3/xx unknown
- 1982-10-18 RO RO82108819A patent/RO89534A/ro unknown
- 1982-10-18 GR GR69556A patent/GR78391B/el unknown
- 1982-10-18 DD DD82244081A patent/DD208822A5/de unknown
- 1982-10-18 JP JP57182681A patent/JPS5890514A/ja active Granted
- 1982-10-18 PT PT75696A patent/PT75696B/pt unknown
- 1982-10-18 IE IE2517/82A patent/IE54371B1/en not_active IP Right Cessation
- 1982-10-18 FR FR8217405A patent/FR2514783B1/fr not_active Expired
- 1982-10-18 SK SK7389-82A patent/SK279535B6/sk unknown
- 1982-10-18 ES ES516620A patent/ES516620A0/es active Granted
- 1982-10-18 EP EP82305521A patent/EP0077670B1/de not_active Expired
- 1982-10-18 DE DE8282305521T patent/DE3279788D1/de not_active Expired
- 1982-10-18 NO NO823467A patent/NO164177C/no not_active IP Right Cessation
- 1982-10-18 CZ CS827389A patent/CZ282154B6/cs unknown
- 1982-10-18 MX MX194810A patent/MX166499B/es unknown
- 1982-10-18 CA CA004136713A patent/CA1341590C/en not_active Expired - Fee Related
- 1982-10-18 BG BG8258326A patent/BG42527A3/xx unknown
- 1982-10-18 GB GB08229661A patent/GB2107718B/en not_active Expired
- 1982-10-18 CH CH6057/82A patent/CH663619A5/de not_active IP Right Cessation
- 1982-10-18 DE DE19823238554 patent/DE3238554A1/de active Granted
- 1982-10-18 DE DE1993175065 patent/DE19375065I2/de active Active
- 1982-10-18 YU YU233582A patent/YU45871B/sh unknown
- 1982-10-18 DK DK460882A patent/DK163187C/da active
- 1982-10-19 RU SU823507549A patent/RU2056460C1/ru active
- 1982-10-19 GT GT198277746A patent/GT198277746A/es unknown
- 1982-10-19 HU HU823305A patent/HU202287B/hu unknown
- 1982-10-19 OA OA57825A patent/OA07233A/xx unknown
- 1982-10-19 PL PL1982238671A patent/PL153202B1/pl unknown
-
1985
- 1985-06-20 US US06/746,813 patent/US4762791A/en not_active Expired - Lifetime
- 1985-09-11 US US06/774,838 patent/US4727138A/en not_active Expired - Lifetime
-
1986
- 1986-11-11 JP JP61268482A patent/JP2515308B2/ja not_active Expired - Lifetime
-
1987
- 1987-08-04 US US07/081,420 patent/US4925793A/en not_active Expired - Lifetime
- 1987-09-04 US US07/094,477 patent/US4929554A/en not_active Expired - Lifetime
- 1987-09-19 MY MYPI87001768A patent/MY102546A/en unknown
-
1988
- 1988-04-08 RU SU884355518A patent/RU2092561C1/ru active
- 1988-04-28 RU SU4355606A patent/RU2107728C1/ru active
- 1988-11-17 SG SG769/88A patent/SG76988G/en unknown
-
1989
- 1989-08-17 HK HK662/89A patent/HK66289A/xx not_active IP Right Cessation
-
1990
- 1990-10-17 JP JP2278835A patent/JPH07106144B2/ja not_active Expired - Lifetime
-
1992
- 1992-10-21 MX MX9206041A patent/MX9206041A/es not_active Application Discontinuation
-
1993
- 1993-05-27 NL NL930040C patent/NL930040I2/nl unknown
- 1993-06-24 LU LU88327C patent/LU88327I2/fr unknown
-
1994
- 1994-12-20 NO NO1994025C patent/NO1994025I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3238554C2 (de) | ||
DE3177288T3 (de) | Reife menschliche Leukozyten-Interferone, Verfahren zu ihrer bacteriellen Herstellung, Zwischenprodukte hierfür und Zusammensetzungen diese enthaltend. | |
DE3588199T2 (de) | Lymphokin-Herstellung und -Reinigung | |
DE3382789T2 (de) | Tierische Interferone, Verfahren bei deren Herstellung, dieselben enthaltende Zusammensetzungen, kodierende DNS-Sequenzen hierfür und diese Sequenzen enthaltende Expressionsvektoren und dadurch transformierte Zellen. | |
US5096705A (en) | Human immune interferon | |
EP0147819B1 (de) | Reinigung von rekombinanten Interleukin-2 | |
EP0271824B1 (de) | Pferde-Gamma-Interferon | |
DD209477A5 (de) | Verfahren zur herstellung von mikroorganismen | |
EP0099084A2 (de) | Verfahren zur Herstellung von Interferon und Expressionsvektoren dafür | |
DD212748A5 (de) | Verfahren zur bildung doppelstraengiger, hybride human-leukozyten-interferone kodierender dns | |
EP0170204B1 (de) | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen | |
DE3586826T2 (de) | Cdna-klone, kodierend fuer peptide mit der wirksamkeit eines menschlichen granulocyte-, makrophage- und eosinophilzellenwachstumsfaktors. | |
AT389892B (de) | Dna-sequenz mit einem gen, das fuer human-interleukin-2 codiert | |
AT394208B (de) | Verfahren zur herstelluung von vektoren | |
AT394207B (de) | Verfahren zur herstellung von human-leukozyteninterferonen | |
DD264706A5 (de) | Verfahren zur Herstellung von Polypeptiden (Pferde-Interforon-Gamma) | |
DE3505060A1 (de) | Neue interferone vom typ i, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen | |
DD251789A5 (de) | Verfahren zur Herstellung von Rekombinanten Pferde- und Hunde-Interferonen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
D2 | Grant after examination | ||
8363 | Opposition against the patent | ||
V448 | Application of spc |
Free format text: PRODUCT NAME: INTERFERON GAMMA, INSBESONDERE INTERFERON GAMMA-1B, INSBESONDERE GENTECHNISCH HERGESTELLT AUS E.COLI K 12 W 3110; REGISTRATION NO/DATE: 26289.00.00, 29378.00.00; 19921216 Spc suppl protection certif: 193 75 064 Filing date: 19930625 |
|
V454 | Spc application withdrawn or to be regarded as withdrawn |
Free format text: PRODUCT NAME: INTERFERON GAMMA, INSBESONDERE INTERFERON GAMMA-1B, INSBESONDERE GENTECHNISCH HERGESTELLT AUS E.COLI K 12 W 3110; REGISTRATION NO/DATE: 26289.00.00, 29378.00.00; 19921216 Spc suppl protection certif: 193 75 064 Filing date: 19930625 |
|
8330 | Complete renunciation | ||
8328 | Change in the person/name/address of the agent |
Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN |